SCHEMBL4491452

SCHEMBL4491452

CCOC(=O)CNC(=O)Nc1n[nH]c2cc(-c3ccccc3F)ccc12

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 3/20 0.57
HDAC1 Q13547 5/20 0.57
HDAC2 Q92769 5/20 0.57
HDAC8 Q9BY41 5/20 0.57
GSK3B P49841 8/20 0.51
PLK4 O00444 1/20 0.47
MAPK13 O15264 1/20 0.47
DAPK3 O43293 1/20 0.47
PRKD3 O94806 1/20 0.47
MAP4K4 O95819 1/20 0.47
CDK1 P06493 1/20 0.47
PIM1 P11309 1/20 0.47
CDK2 P24941 1/20 0.47
MARK3 P27448 1/20 0.47
FLT4 P35916 1/20 0.47
MAPK8 P45983 1/20 0.47
MAPK9 P45984 1/20 0.47
CDK8 P49336 1/20 0.47
CLK2 P49760 1/20 0.47
MAPK12 P53778 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4504382 0.87 HDAC6 (0.64) HDAC6HDAC1HDAC2HDAC8GSK3B
SCHEMBL4485804 0.86 GSK3B (0.58) HDAC6HDAC1HDAC2HDAC8GSK3B
SCHEMBL4479328 0.85 HDAC6 (0.62) HDAC6HDAC1HDAC2HDAC8GSK3B
SCHEMBL4504427 0.81 HDAC1 (0.61) HDAC6HDAC1HDAC2HDAC8GSK3B
SCHEMBL4482240 0.80 AAK1 (0.61) HDAC6HDAC1HDAC2HDAC8GSK3B
SCHEMBL4482259 0.79 HDAC1 (0.67) HDAC6HDAC1HDAC2HDAC8GSK3B
SCHEMBL4496605 0.79 HDAC6 (0.64) HDAC6HDAC1HDAC2HDAC8GSK3B
SCHEMBL12886373 0.76 GSK3B (0.59) HDAC6HDAC1HDAC2HDAC8GSK3B
SCHEMBL4502956 0.75 HDAC6 (0.74) HDAC6HDAC1HDAC2HDAC8GSK3B
SCHEMBL12886030 0.75 GSK3B (0.53) HDAC6HDAC1HDAC2HDAC8GSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1506176-B1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PFIZER ITALIA SRL (IT) 2013-04-24 EP disclosed
US-7632854-B2 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2009-12-15 US disclosed
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2006-05-18 US disclosed
EP-1506176-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM Pharmacia Italia S.p.A. (IT) 2005-02-16 EP disclosed
WO-2003097610-A1 AMINOINDAZOLE DERIVATIVES ACTIVE AS KINASE INHIBITORS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM PHARMACIA ITALIA S.P.A. (IT) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106083-A1 Aminoindazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K15, MAP3K3, MAP3K20 HDAC6 675/4885HDAC1 706/4885HDAC2 945/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.